Cytokinetics, Incorporated reported $68M of revenue over the trailing twelve months, −21% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $68M (to Q2 2026). Net income: −$894M, trailing twelve months to Q2 2026. Free cash flow: −$581M, trailing twelve months to Q2 2026. Operating margin: −2798%, trailing twelve months to Q2 2026.

CYTKCytokinetics, Incorporated

Healthcare

$62.93+29% 1Y

$62.93

$47.8352 weeks$84.88

CYTK as reported

Cytokinetics, Incorporated reported $68M of revenue over the trailing twelve months, −21% on the year before. 9 reported series are charted on this page, each one as filed.

$68M

Revenue, trailing twelve months · to Q2 2026 · −21% against the twelve months before

Net income: −$894M
Net income · +47% year on year · trailing twelve months to Q2 2026
Free cash flow: −$581M
Free cash flow · +32% year on year · trailing twelve months to Q2 2026
Operating margin: −2798%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CYTK, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$68M	−21%	Q2 2026
Net income	−$894M	+47%	Q2 2026
EPS	−$7.22	+42%	Q2 2026
Operating margin	−2798%	n/a	Q2 2026
Net margin	−4651%	n/a	Q2 2026
ROE	220%	n/a	Q2 2026
ROA	−55%	n/a	Q2 2026
ROIC	41%	n/a	Q2 2026
Free cash flow	−$581M	+32%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.